Globus Medical Reports Robust Q1 Performance, Exceeding Expectations and Raising Full-Year EPS Guidance

summarizeSummary

Globus Medical reported strong first-quarter 2026 financial results, with worldwide net sales up 27% and diluted EPS increasing by 66.6%, leading the company to raise its full-year non-GAAP EPS guidance.

check_boxKey Events

• Strong Q1 Revenue Growth

  Worldwide net sales for the first quarter of 2026 reached $759.9 million, marking a 27.0% increase over the same period last year. Base business sales, excluding Nevro, grew by 13.2%.

• Significant EPS Increase

  GAAP diluted earnings per share (EPS) for Q1 2026 was $0.90, a 66.6% increase from $0.54 in Q1 2025. Non-GAAP diluted EPS also rose significantly to $1.12, up 64.7% year-over-year.

• Full-Year EPS Guidance Raised

  The company updated its full-year 2026 non-GAAP fully diluted EPS guidance to a range of $4.70 to $4.80, an increase from the previous range of $4.40 to $4.50, while reaffirming revenue guidance.

• Nevro Acquisition Contribution

  The Nevro acquisition contributed $82.7 million to net sales in the first quarter, playing a role in the overall revenue growth.

auto_awesomeAnalysis

Globus Medical's first-quarter results demonstrate strong operational execution and successful integration of the Nevro acquisition. The significant revenue growth, driven by both organic expansion in core spine and contributions from Nevro, coupled with substantial increases in GAAP and non-GAAP EPS, signals robust underlying business health. The decision to raise full-year non-GAAP EPS guidance indicates management's confidence in sustained profitability and synergy realization, which should bolster investor sentiment and potentially drive stock performance.